NS-TLR |
|
Vaxjo ID |
403 |
|
Vaccine Adjuvant Name |
NS-TLR |
|
Alternative Names |
NS-TLR may be referred to as nanoshell-TLR7 conjugates. |
|
Adjuvant VO ID |
VO_0005749
|
|
Description |
NS-TLR is a synthetic vaccine adjuvant made of a TLR7 agonist, 2-methoxyethoxy-8-oxo-9-(4-carboxybenzyl)adenine (1V209) conjugated to silica nanoshells that induces a Th1-biased immune profile. |
|
Stage of Development |
Research |
|
Host Species for Testing |
Mouse |
|
Components |
silica nanoshells-TLR7 conjugates (NS-TLR) depends on nanoshell size and ligand coating density |
|
Structure |
NS-TLR is composed of hollow silica nanoshells functionalized with TLR7 agonists on their surface, allowing for targeted immune activation. |
|
Preparation |
NS-TLR is prepared by conjugating the TLR7 agonist (1V209) to silica nanoshells through established surface modification techniques. |
|
Dosage |
In the studies, NS-TLR was used in formulations with doses of 20 ug of OVA (ovalbumin) as a model antigen. |
|
Function |
The results show that the TLR7 ligand conjugated to silica nanoshells is capable of activating an inflammasome pathway to enhance both innate immune-stimulatory and adjuvant potencies of the TLR7 agonist, thereby broadening applications of innate immune stimulators. |
|
Safety |
The article indicates that NS-TLR has a low toxicity profile and enhances the immune response without significant adverse effects. |
| References |
Huang et al., 2019: Huang CH, Mendez N, Echeagaray OH, Weeks J, Wang J, Vallez CN, Gude N, Trogler WC, Carson DA, Hayashi T, Kummel AC. Conjugation of a Small-Molecule TLR7 Agonist to Silica Nanoshells Enhances Adjuvant Activity. ACS applied materials & interfaces. 2019; 11(30); 26637-26647. [PubMed: 31276378].
|
